COMPANY OVERVIEW

Concentric Analgesics, Inc. is a privately-held, clinical-stage biopharmaceutical company focused on discovering and developing novel, non-opioid therapeutics for the management of acute and chronic pain.

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

https://www.concentricanalgesics.com/

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Mar 30, 2022

Concentric Analgesics Announces Positive Results from Pilot Phase 2 Clinical Trial of Vocacapsaicin in Open Laparotomy for Repair of Abdominal Ventral Hernia

Feb 2, 2022

Concentric Analgesics Forges Important Phase 3 Clinical Relationships for Vocacapsaicin, a Non-Opioid Pain Therapy Targeting TRPV1 Receptor

Jan 26, 2022

Concentric Analgesics Announces Completion of $20 Million Financing and Appoints Two New Board Members as it Prepares to Initiate Registration-Enabling Phase 3 Studies for Vocacapsaicin

Nov 22, 2021

Concentric Analgesics Announces Poster Presentation of Positive Vocacapsaicin Data from Total Knee Arthroplasty Phase 2 Study at the 2021 American Academy of Hip and Knee Surgeons Annual Meeting

May 11, 2021

Concentric Analgesics Announces Podium Presentation of Vocacapsaicin Clinical Data at 46th Annual ASRA Meeting

For More Press Releases

---